Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jim Christensen

Internal Medicine Las Vegas, NV Medical Doctor

NPI 1700830015 CMS profile 350004

1800 W. Charleston Blvd., Las Vegas, NV 89102

Open in the dashboard

General payments

$5,260

278 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jim Christensen of Las Vegas, NV is reported in the CMS Open Payments database as having received $5,260 across 278 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $292 13
2024 General $20 1
2021 General $1,034 52
2020 General $1,001 54
2019 General $2,913 158

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jim Christensen
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jim Christensen were reported at $292. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jim Christensen Internal Medicine median Middle half National median
2019 $2,913 $159 $48–$570 $163
2020 $1,001 $119 $33–$402 $114
2021 $1,034 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $20 $154 $47–$537 $164
2025 $292 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $975 47 payments
  2. CSL Behring $588 35 payments
  3. ViiV Healthcare Company $461 13 payments
  4. Genzyme Corporation $310 13 payments
  5. Pfizer Inc. $309 33 payments
  6. Merck Sharp & Dohme Corporation $289 6 payments
  7. Pharming Healthcare, Inc. $258 5 payments
  8. Regeneron Healthcare Solutions, Inc. $237 26 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $233 11 payments
  10. Shire North American Group Inc $220 13 payments
  11. Other $1,378 76 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,111 266 payments
  2. Education $149 12 payments
Products named General payments · program years 2019–2025
  1. Haegarda $560 31 payments
  2. NUCALA Respiratory $454 26 payments
  3. DOVATO $407 10 payments
  4. EUCRISA $309 33 payments
  5. DUPIXENT Immunology $299 14 payments
  6. NUCALA Immunology $295 10 payments
  7. DUPIXENT Immunology $261 13 payments
  8. RUCONEST $258 5 payments
  9. DUPIXENT Inflammation And Immunology $237 26 payments
  10. TAKHZYRO $236 12 payments
  11. Other $2,368 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

278 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record